Alpha Tau Medical Ltd (DRTS)

PAVmed (NASDAQ:PAVM) versus Alpha Tau Medical (NASDAQ:DRTS) Critical Contrast

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success

Alpha Tau Medical (NASDAQ:DRTS) Trading 7.1% Higher – Here’s Why

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

New Strong Sell Stocks for July 7th

New Strong Sell Stocks for July 2nd

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Alpha Tau Medical: A Lot Of Shots On Goal

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears